Zika virus vaccine composition and application thereof

Patent metadata

Field	Value
Publication number	US-10501529-B2
Application number	US-201816037502-A
Country	US
Kind code	B2
Filing date	Jul 17, 2018
Priority date	Feb 13, 2018
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

Provided herein are a mutant envelope protein of Zika virus and a nucleic acid molecule including a nucleotide sequence encoding the mutant envelope protein. The mutant envelope protein, which preferably has a threonine substitution at 105th position, or an asparagine substitution at 248th position and a threonine substitution at 250th position in an amino acid sequence of SEQ ID NO: 1, includes an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus. Also provided herein is a vaccine composition, including the mutant envelope protein or a recombinant virus including the nucleic acid molecule. Also provided herein is a method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, including administering to a subject in need thereof an effective amount of a vaccine composition including the mutant envelope protein of Zika virus.

First claim

What is claimed is:

1. A mutant envelope protein of Zika virus, comprising an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus, wherein the mutant envelope protein of Zika virus has an asparagine substitution at 248 th position and a threonine substitution at 250 th position in an amino acid sequence of SEQ ID NO: 1.

2. A nucleic acid molecule, comprising a nucleotide sequence encoding the mutant envelope protein of Zika virus according to claim 1 .

3. A vaccine composition, comprising the mutant envelope protein of Zika virus according to claim 1 .

4. The vaccine composition according to claim 3 , further comprising a precursor membrane protein of Zika virus.

5. A vaccine composition, comprising a recombinant virus including the nucleic acid molecule according to claim 2 .

6. The vaccine composition according to claim 5 , wherein the recombinant virus comprises a gene encoding a precursor membrane protein of Zika virus.

7. The vaccine composition according to claim 5 , wherein the recombinant virus is a recombinant adenovirus.

8. A method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, comprising administering to a subject in need thereof an effective amount of a vaccine composition including a mutant envelope protein of Zika virus, wherein the mutant envelope protein of Zika virus comprises an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus, wherein the mutant envelope protein of Zika virus has an asparagine substitution at 248 th position and a threonine substitution at 250 th position in an amino acid sequence of SEQ ID NO: 1.

9. The method according to claim 8 , wherein the mutant envelope protein of Zika virus is expressed by a recombinant virus.

10. The method according to claim 9 , wherein the recombinant virus is a recombinant adenovirus.

Assignees

• Univ Nat Tsing Hua

Inventors

• Wu Suh-Chin
• Yang Shao-Ping
• Lin Hsiao-Han

Classifications

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• C12N2770/24122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K14/1825

  Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue · CPC title